The Genomics in Cancer Care Market is expanding rapidly as liquid biopsy, minimal residual disease (MRD) testing, and non-invasive genomic monitoring become integral components of cancer care. With the market estimated at around USD 24–25 billion in 2025 and expected to surpass USD 100 billion by 2035 at CAGRs exceeding 20–25%, genomics is shifting from a specialty tool to a routine element of oncology workflows.

Liquid biopsy is one of the most disruptive forces in this market. By analyzing circulating tumor DNA (ctDNA) and other tumor-derived materials in blood, clinicians can detect actionable mutations, monitor treatment response, and identify emerging resistance—without repeated tissue biopsies. This is particularly valuable for lung cancer, breast cancer, colorectal cancer, and other solid tumors where serial biopsies are challenging or risky.

MRD testing is another major growth engine. Highly sensitive genomic assays can detect tiny amounts of residual disease in blood or bone marrow after treatment, helping oncologists predict relapse earlier and adjust therapy proactively. This approach is already transforming management in hematologic malignancies like leukemias and lymphomas and is gradually extending into solid tumors.

FAQs
Q1. What is liquid biopsy used for?
Detecting tumor mutations, tracking response to therapy, and identifying resistance through blood instead of tissue biopsies.

Q2. Why is MRD testing important?
It helps identify patients at high risk of relapse early, enabling timely therapeutic decisions.

Tags: liquid biopsy, MRD testing, ctDNA, genomics in cancer care, non-invasive monitoring, cancer diagnostics, precision oncology